{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:56:09Z","timestamp":1789084569378,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["096527"],"award-info":[{"award-number":["096527"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["091625"],"award-info":[{"award-number":["091625"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12910-018-0259-4","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T07:23:15Z","timestamp":1520320995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Phaik Yeong","family":"Cheah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Steinkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"key":"259_CR1","unstructured":"Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health Related Research Involving Humans 2016. \n                    https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf\n                    \n                  . Accessed 28 Feb 2018."},{"key":"259_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199709183371212","volume":"337","author":"P Lurie","year":"1997","unstructured":"Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997;337:853\u20136.","journal-title":"N Engl J Med"},{"key":"259_CR3","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(14)61315-5","volume":"384","author":"A Rid","year":"2014","unstructured":"Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384:1896\u20139.","journal-title":"Lancet"},{"key":"259_CR4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1056\/NEJMp1414145","volume":"371","author":"E Cox","year":"2014","unstructured":"Cox E, Borio L, Temple R. Evaluating Ebola therapies--the case for RCTs. N Engl J Med. 2014;371:2350\u20131.","journal-title":"N Engl J Med"},{"key":"259_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/15265161.2015.1010993","volume":"15","author":"AL Caplan","year":"2015","unstructured":"Caplan AL, Plunkett C, Levin B. Selecting the right tool for the job. Am J Bioeth. 2015;15:4\u201310.","journal-title":"Am J Bioeth"},{"key":"259_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(14)61734-7","volume":"384","author":"C Adebamowo","year":"2014","unstructured":"Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy AF, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384:1423\u20134.","journal-title":"Lancet"},{"key":"259_CR7","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S0140-6736(14)61653-6","volume":"385","author":"AL Caplan","year":"2015","unstructured":"Caplan AL. Morality in a time of Ebola. Lancet. 2015;385:e16\u20137.","journal-title":"Lancet"},{"key":"259_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12879-015-1276-2","volume":"15","author":"IMPROV Study Group","year":"2015","unstructured":"IMPROV Study Group. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis. 2015;15:558.","journal-title":"BMC Infect Dis"},{"key":"259_CR9","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1371\/journal.pntd.0000774","volume":"4","author":"CA Guerra","year":"2010","unstructured":"Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, et al. The international limits and population at risk of plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774.","journal-title":"PLoS Negl Trop Dis"},{"key":"259_CR10","unstructured":"World Health Organisation. World Malaria Report 2015. \n                    http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2015\/report\/en\/\n                    \n                   Accessed 22 Aug 2016."},{"key":"259_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2307\/3279032","volume":"62","author":"GR Coatney","year":"1976","unstructured":"Coatney GR. Relapse in malaria--an enigma. J Parasitol. 1976;62:3\u20139.","journal-title":"J Parasitol"},{"key":"259_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in plasmodium vivax malaria. Malar J. 2011;10:297.","journal-title":"Malar J"},{"key":"259_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1475-2875-11-280","volume":"11","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, von Seidlein L, Nosten F, Baird K, White NJ, et al. Primaquine radical cure of plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.","journal-title":"Malar J"},{"key":"259_CR14","unstructured":"World Health Organisation. Guidelines for the treatment of malaria 2015. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/162441\/1\/9789241549127_eng.pdf\n                    \n                  . Accessed 22 Aug 2016."},{"key":"259_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12936-015-0896-8","volume":"14","author":"B Ley","year":"2015","unstructured":"Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377.","journal-title":"Malar J"},{"key":"259_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2307\/3528434","volume":"33","author":"FG Miller","year":"2003","unstructured":"Miller FG, Brody H. A critique of clinical equipoise. Therapeutic misconception in the ethics of clinical trials. The Hastings Cent Rep. 2003;33:19\u201328.","journal-title":"The Hastings Cent Rep"},{"key":"259_CR17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4269\/ajtmh.2008.78.736","volume":"78","author":"S Krudsood","year":"2008","unstructured":"Krudsood S, Tangpukdee N, Wilairatana P,P, Phophak N, Baird JK, Brittenham GM, et al. High-dose primaquine regimens against relapse of plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78:736\u201340.","journal-title":"Am J Trop Med Hyg"},{"key":"259_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.4269\/ajtmh.1977.26.562","volume":"26","author":"DF Clyde","year":"1977","unstructured":"Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg. 1977;26:562\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"259_CR19","unstructured":"World Medical Association. Declaration of Helsinki 2013. \n                    https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/\n                    \n                  . Accessed 28 Feb 2018."},{"key":"259_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1086\/381709","volume":"189","author":"EJ Emanuel","year":"2004","unstructured":"Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Inf Dis. 2004;189:930\u20137.","journal-title":"J Inf Dis"}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-018-0259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T19:19:26Z","timestamp":1551813566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedethics.biomedcentral.com\/articles\/10.1186\/s12910-018-0259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s12910-018-0259-4","relation":{},"ISSN":["1472-6939"],"issn-type":[{"value":"1472-6939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]},"assertion":[{"value":"5 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RNP is the principal investigator of the IMPROV study. RNP, PYC and LvS are members of the IMPROV Trial Management Group. We declare no other interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}